Could a heart drug help kidney patients? new trial tests finerenone for membranous nephropathy
NCT ID NCT06573411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding finerenone to standard blood pressure medications can lower protein in the urine of people with primary membranous nephropathy, a kidney condition that can lead to kidney failure. About 116 adults will be randomly assigned to receive either finerenone plus standard care or standard care alone. The main goal is to see if protein levels drop more with the combination after 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- finerenone
- What this could lead to
- If successful, this could offer a new way to reduce protein leakage in the urine for people with primary membranous nephropathy, potentially slowing kidney damage.
- What could go wrong
- This is a relatively small Phase 4 trial with 116 participants, and the main outcome is a lab measure (proteinuria) rather than long-term kidney health. The drug may not show meaningful benefit over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wei Chen
RECRUITINGGuangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a pill calm the immune attack on kidneys?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- New gel could outperform standard therapy for kidney disease